Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-08-14
2010-12-07
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252020, C514S252040
Reexamination Certificate
active
07846932
ABSTRACT:
A subject of the invention is the compounds of formula (I);in which R1, R2, R3, R4and R have the meanings indicated in the description, their preparation process, their use as medicaments having an antagonist activity on the vitronectin receptor and the pharmaceutical compositions containing them.
REFERENCES:
patent: 6723727 (2004-04-01), Peyman et al.
patent: 6992187 (2006-01-01), Peyman et al.
patent: 7582640 (2009-09-01), Ruxer et al.
patent: 2008/0058348 (2008-03-01), Lefrancois et al.
patent: 100 42 655 A! (2002-03-01), None
patent: 0 528 586 (1995-02-01), None
patent: 0 528 587 (1995-02-01), None
patent: 0 820 991 (1998-01-01), None
patent: 0 933 367 (1999-08-01), None
patent: 1 065 207 (2001-01-01), None
patent: 10-182645 (1998-07-01), None
patent: WO-94/08577 (1994-04-01), None
patent: WO-94/12181 (1994-06-01), None
patent: WO-95/32710 (1995-12-01), None
patent: WO-96/00574 (1996-01-01), None
patent: WO 96/00730 (1996-01-01), None
patent: WO-98/00395 (1998-01-01), None
patent: WO 99/32457 (1999-07-01), None
patent: WO 99/37621 (1999-07-01), None
patent: WO-99/50249 (1999-10-01), None
patent: WO-00/78317 (2000-12-01), None
patent: WO-01/02399 (2001-01-01), None
patent: WO-02/18384 (2002-03-01), None
patent: WO 2004/048375 (2004-06-01), None
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
Stella, Valentino J. Expert Opinion of Therapeutic Patents, Prodrugs as therapeutics, 2004 14(3): 277-280.
Wolff et al. (Burger's Medicinal Chemistry, 5th Ed., vol. 1, pp. 975-977, 1994).
Testa, Bernard, Biochemical Pharmacology, Prodrug Research: futile or fertile? 68 (2004) 2097-2106.
Ettmayer, Peter, Medicinal Chemistry, Lessons Learned from Marketed and Investigational Prodrugs, 47(10) (2004) 2394-2404.
Kwon, Younggil, Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scentists Jun. 24, 2001, p. 213, paragraph 3.
“Metabolomics,” Retrieved online via the Internet [Oct. 16, 2008] URL: www.en.wikipedia.org/wiki/Metabolomics.
Agrez et al., The ανβ6 Integrin induces gelatinase B secretion in colon cancer cells, Int. J. Cancer, 81, pp. 90-97,1999.
Antonov et al., Medline Abstract (American Journal of Pathology, vol. 165, Issue 1, pp. 247-258) Jul. 2004.
Brooks et al, Integrin ανβ3antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, Cell (1994) 79: 1157-1164.
Brooks et al., Integrin ανβ3: A therapeutic target, DN&P, 10(8), pp. 456-461, Oct. 1997.
Brown et al., Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis, Cardiovascular Research (1994), 28:1815-1820.
English Translation of Japanese Office Action dated Dec. 8, 2009 for Japanese App. No. 2004-554592.
Evans, Reduction of Aminopyrimidines., Hydropyrimidines: Part III., J. Chem. Soc. (1964), p. 2450-2455.
Fisher et al., Inhibition of osteoclastic bone absorption in vivo by eshistatin, an arginyl-glycyl-aspartyl(RGD)-containing protein, Endocrinology (1993), 132(3):1411-1413.
Friedlander et al, Definition of two angiogenic pathways by distinct ανintegrins, Science (1995), 270:1500-1502.
Gladson et al., Vitronectin Expression in Differentiating Neuroblastic Tumors, American Journal of Pathology, vol. 150, No. 5, pp. 1631-1646, May 1997.
Henry et al, Vitronectin receptor- ανβ3intigren-Antagonists: Chemical and structural requirements for activity and selectivity, Mini Reviews in Medicinal Chemistry, 2:531-542, 2002.
Horton et al., Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts, Exp. Cell. Res. (1991), 195: 368-375.
Kim et al., Vitronectin-driven Human Keratinocyte Locomotion Is Mediated by the ανβ5Integrin Receptor, The Journal of Biological Chemistry, vol. 269, No. 43, pp. 26928-26932, Oct. 1994.
Konig et al, Perchloric acid in peptide chemistry, Peptides (1990), p. 143-145.
Nip et al., The role of the Integrin vitronectin receptor, ανβ3in melanoma metastasis, Cancer and Metastasis Reviews, 14, pp. 241-252, 1995.
Pytela et al., Arginine-Glycine-Aspartic acid adhesion receptors, Methods in Enzymology (1987) 144:475-489.
Raynal et al., Bone Sialoprotein Stimulates in vitro Bone Resorption, Endocrinology, vol. 137, No. 6, pp. 2347-2354,1996.
Sato et al., Echistatin is a potent inhibitor of bone resorption in culture, J. Cell. Bio. (1990), 111:1713-1723.
Schvartz et al., Vitronectin, The International Journal of Biochemistry & Cell Biology, 31, pp. 539-544, 1999.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.
Stilz et al., Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold, J. Med. Chem.(2001), 44:1158-1176.
Wermuth, C.G., The Practice of Medicinal Chemistry, (1998) 1:273-297—No translation.
Advisory Action dated Apr. 1, 2009 for U.S. Appl. No. 10/536,028.
Interview Summary dated Jan. 22, 2010 for U.S. Appl. No. 12/245,622.
Interview Summary dated Feb. 26, 2009 for U.S. Appl. No. 10/536,028.
Notice of Allowance dated Mar. 18, 2010 for U.S. Appl. No. 12/245,622.
Notice of Allowance dated Apr. 24, 2009 for U.S. Appl. No. 10/536,028.
Notice of Allowance dated May 6, 2009 for U.S. Appl. No. 11/596,597.
Notice of Allowance dated Aug. 28, 2009 for U.S. Appl. No. 11/596,597.
Office Action dated Apr. 2, 2008 for U.S. Appl. No. 10/536,028.
Office Action dated Jun. 5, 2008 for U.S. Appl. No. 11/596,597.
Office Action dated Oct. 2, 2009 for U.S. Appl. No. 12/245,622.
Office Action dated Oct. 24, 2008 for U.S. Appl. No. 11/596,597.
Office Action dated Dec. 8, 2008 for U.S. Appl. No. 10/536,028.
Heckmann Bertrand
Lefrancois Jean-Michel
Foley & Lardner LLP
Galapagos SAS
Reiter Stephen E.
Saeed Kamal A.
Shterengarts Samantha L
LandOfFree
Methods for the use of pyrimidine derivatives which are... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the use of pyrimidine derivatives which are..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the use of pyrimidine derivatives which are... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4235797